Claude Bernard University Lyon 1 (UCBL), the lead institution of the RHU, is responsible for coordinating the project, conducting fundamental research on the mechanisms of action of HEPHA-440, and managing the preclinical toxicology studies.
The company HEPHAISTOS is responsible for the production of so-called "GMP" drug batches, meaning they comply with Good Manufacturing Practices, as well as for the valorization.
The Hospices Civils de Lyon (HCL) oversee the implementation and conduct of clinical trials, as well as the monitoring of the drug’s fate within the human body.
The Léon Bérard Center (CLB) will host part of the clinical trials and will be responsible for analyzing clinical data, alongside studying the immune mechanisms of HEPHA-440 in humans.
